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enal Artery Stenting
s it Ready for Primetime?*
htisham Mahmud, MD, FACC
an Diego, California
he first percutaneous transluminal renal angioplasty
PTRA) for the treatment of atherosclerotic renal artery
tenosis (RAS) was performed in 1977 (1), the same year as
he first coronary angioplasty (2). Whereas percutaneous
oronary revascularization is now a routine practice for the
reatment of coronary artery disease, the diagnostic and
herapeutic strategies for appropriately treating patients
ith RAS have not developed. Why not? The answers to
his question are controversial, and factors complicating the
ssue include the often-asymptomatic nature of RAS and
See page 776
onflicting data regarding the benefits of treatment. Patients
ith RAS may develop poorly controlled hypertension,
rogressive renal insufficiency, or renal atrophy, all of which
re usually asymptomatic in the early stages. Previous
tudies have used the cure of hypertension, rather than an
mprovement in hypertension, as an end point in renal
evascularization studies, and this confounds the issue,
specially when both essential hypertension and renovascu-
ar hypertension are present in the same patient. Further-
ore, there is inconsistency in published reports regarding
he benefit of non-surgical renal revascularization for treat-
ng hypertension or preventing renal dysfunction.
OLE OF MEDICAL THERAPY AND
ALLOON ANGIOPLASTY IN THE TREATMENT OF RAS
edical therapy is preferred over renal revascularization for
atients with atherosclerotic RAS and advanced renal dis-
ase as manifested by chronic renal failure (creatinine 2.5
g/dl with unilateral RAS), proteinuria (1 g/day), diffuse
ntrarenal vascular disease, renal atrophy (kidney length
7.0 cm), or a resistive index 80 (3). Although PTRA is
elt to be the treatment of choice for fibromuscular dysplasia
eading to RAS, the data supporting this approach are
rimarily descriptive and from the pre-stent era (4). How-
ver, in cases of atherosclerotic RAS, which account for the
ast majority of patients with hypertension and RAS, the
esults of PTRA have been disappointing. In the Dutch
enal Artery Stenosis Intervention Cooperative
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.c
From the Cardiac Catheterization Laboratory, University of California, San Diego,
alifornia.DRASTIC) trial, 106 patients with atherosclerotic RAS,
ypertension despite treatment with 2 antihypertensive
edications, and a serum creatinine 2.3 mg/dl were
andomized to PTRA versus medical therapy, and this study
emonstrated that PTRA offered little benefit over medical
herapy for the treatment of hypertension (5). However,
imitations of this study included the enrollment of patients
ith insignificant RAS, a 44% cross-over from medical
herapy to PTRA, and low use of stents (20%). Neverthe-
ess, due to the scant data that previously existed on the
ubject, this study had a broad impact on clinical practice,
nd enthusiasm for percutaneous revascularization of pa-
ients with atherosclerotic RAS diminished.
OLE OF STENTING IN THE TREATMENT OF RAS
he frequent involvement of the ostial renal artery in
therosclerotic RAS leads to high elastic recoil with PTRA,
nd subsequently high restenosis rates of 42% to 47% (6,7).
he problem of elastic recoil is alleviated with the use of
ndovascular stents, which provide mechanical scaffolding.
esults from observational studies have demonstrated that
enal stenting is safe and effective in reducing blood pressure
8,9), whereas a randomized trial proved the superiority of
enal stenting over PTRA for immediate procedural success
88% stent vs. 57% PTRA) and lowering restenosis (14%
tent vs. 48% PTRA) (10). However, concerns have existed
egarding the deleterious effects of renal stenting on renal
unction, especially for patients with chronic renal insuffi-
iency (8). These concerns have largely been dismissed by
ecent studies demonstrating improvement or stabilization
f renal function after unilateral or bilateral renal stenting in
atients with atherosclerotic RAS and progressive renal
nsufficiency (11,12).
The study by Rocha-Singh et al. (13) in this issue of the
ournal is the first prospective multicenter study in which
atients with atherosclerotic RAS were treated with
alloon-expandable stents and evaluated by independent
ngiographic and Duplex core laboratories to determine the
uccess of the index procedure and demonstrate long-term
fficacy at follow-up examinations. The investigators en-
olled 208 hypertensive patients with de novo or restenotic
esions 70% at the aorto-ostial renal artery junction who
ere not successfully treated with PTRA (residual stenosis
50%, flow-limiting dissection, persistent peak-to-peak
ranslesional pressure gradient of 20 mm Hg). Acute
echnical success was achieved in 94.9% of the lesions
reated with reduction in diameter stenosis from 61.5% to
2.2%. The primary end point of the study was the
ine-month restenosis rate as determined by duplex ultra-
onography or angiography and reported to be 17.4%. Renal
tenting resulted in improvement of blood pressure from
68  25/82  13 mm Hg to 149  25/77  12 mm Hg
ith a reduction in the number of antihypertensive medi-
ations from 2.8  0.9 to 2.3  1.3 between baseline and
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September 6, 2005:784–6 Editorial Commentwo-year follow-up (p  0.001 for all). Serum creatinine
ncreased slightly from 1.36  0.52 to 1.46  0.81 (p 
.04) between baseline and two-year follow-up but did not
hange significantly in the subgroup of patients with base-
ine renal insufficiency (serum creatinine 2.0 mg/dl).
ajor adverse event rate for the two-year period was 19.7%,
ith target lesion revascularization accounting for the ma-
ority of events.
Although this is not a randomized clinical trial, it is an
mportant study that demonstrates renal stenting signifi-
antly reduces blood pressure and the number of antihyper-
ensive medications required by patients with renovascular
ypertension. This study also confirms that bilateral renal
tenting (performed in 21% of study patients) and renal
tenting in patients with chronic renal insufficiency is safe. It
s of concern that only 47% of the study cohort had any
owering of their blood pressure in response to renal
tenting. Therefore, at least one-half of the patients in this
tudy had insignificant RAS, parenchymal renal disease, or
ssential hypertension, and the 20 mm Hg systolic blood
ressure lowering in the overall cohort likely underestimates
he degree of beneficial effect in the patients who actually
espond to renal stenting. Efforts need to be directed toward
dentifying physiological and biological markers that may
redict response to renal stenting for blood pressure lower-
ng and renal function preservation. Recently, Silva et al.
14) reported that 77% of patients with RAS who had a
rain naturetic peptide level 80 pg/ml had an improve-
ent in their blood pressure after renal stenting, whereas no
esponse was noted in patients with a level 80 pg/ml. If
his is confirmed in a larger patient cohort, then this could
e one marker that could help identify patients likely to
enefit from the procedure, rather than exposing patients
ith essential hypertension to the risks of renal stenting.
Hypertension affects more than 25% of the worldwide
dult population (15). Although the vast majority have
ssential hypertension, it is important to identify patients
ith secondary treatable causes of hypertension, especially
therosclerotic RAS, the most common cause of renovas-
ular hypertension (16). Clinical clues to the presence of
AS include: onset of hypertension after age 55 years,
xacerbation of well-controlled hypertension, malignant
ypertension, progressive renal insufficiency, azotemia with
nitiation of angiotensin-converting enzyme inhibitor ther-
py, renal atrophy, or cardiac dysfunction (3). Noninvasive
ools for detecting RAS have sensitivities ranging from 70%
o 100%, whereas their specificity varies greatly between
0% to 90% (3). Therefore, in the context of high clinical
uspicion, a renal artery angiogram in multiple views is
esirable. Importantly, among patients undergoing cardiac
atheterization not previously suspected of having athero-
clerotic RAS who have any of the following criteria: 1)
evere hypertension; 2) unexplained renal dysfunction; 3)
cute pulmonary edema with hypertension; or 4) severe
therosclerosis, 39% were found to have renal atherosclero-
is, with 14.3% having 50% RAS (17).The currently reported study demonstrates that the im-
rovement in blood pressure control after renal stenting is
aintained at the two-year interval. However, these results
re obtained at the expense of a 17.4% restenosis rate with
enal stenting, and a well-tested option for the treatment of
enal stent restenosis is not available. Brachytherapy and
utting balloon atherotomy have been used for renal artery
n-stent restenosis (18,19), but long-term outcomes are
nknown. Although surgical revascularization is effective for
he treatment of RAS, its role will remain limited and likely
ot be subjected to a randomized clinical trial against renal
tenting due to the higher morbidity and mortality of the
urgical approach.
Drug-eluting stents and distal protection devices have
een used for the treatment of atherosclerotic RAS (20,21),
ut their roles require further elucidation. Long-term out-
ome data with stroke, myocardial infarction, left ventricular
ypertrophy, congestive heart failure, renal failure, and
eath as end points after renal stenting need to be obtained,
nd some of these data are being gathered in the ongoing
ardiovascular Outcomes in Renal Atherosclerotic Lesions
CORAL) study (22). This National Heart, Lung, and
lood Institute-sponsored study is testing the hypothesis of
hether renal ischemia with its consequent neuroendocrine
ctivation contributes to adverse cardiovascular and renal
vents, independently of the blood pressure achieved. The
esults of this trial are years away, but based on the currently
vailable data and reported study, it appears that in selected
atients, renal artery stenting is indeed ready for primetime!
atients with atherosclerotic RAS who are hypertensive
blood pressure 140/90 mm Hg) despite treatment with
2 antihypertensive medications, with a serum creatinine
3.0 mg/dl and a kidney 8 cm in length should be
onsidered for renal artery stenting. In such patients, good
rocedural outcomes and the long-term benefit of improved
lood pressure control and renal function preservation can
e expected.
eprint requests and correspondence: Dr. Ehtisham Mahmud,
ardiac Catheterization Laboratory, University of California, San
iego, 200 West Arbor Drive, San Diego, California 92103-8784.
-mail: emahmud@ucsd.edu.
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